| Literature DB >> 29852857 |
Jonas Schubert1,2, Munish Chanana3,4,5.
Abstract
Within the last two decades, the field of nanomedicine has not developed as successfully as has widely been hoped for. The main reason for this is the immense complexity of the biological systems, including the physico-chemical properties of the biological fluids as well as the biochemistry and the physiology of living systems. The nanoparticles' physicochemical properties are also highly important. These differ profoundly from those of freshly synthesized particles when applied in biological/living systems as recent research in this field reveals. The physico-chemical properties of nanoparticles are predefined by their structural and functional design (core and coating material) and are highly affected by their interaction with the environment (temperature, pH, salt, proteins, cells). Since the coating material is the first part of the particle to come in contact with the environment, it does not only provide biocompatibility, but also defines the behavior (e.g. colloidal stability) and the fate (degradation, excretion, accumulation) of nanoparticles in the living systems. Hence, the coating matters, particularly for a nanoparticle system for biomedical applications, which has to fulfill its task in the complex environment of biological fluids, cells and organisms. In this review, we evaluate the performance of different coating materials for nanoparticles concerning their ability to provide colloidal stability in biological media and living systems. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Nanoparticles; biological media; biopolymers; coating materials; colloidal stability; polymeric coatings; protein corona.
Mesh:
Substances:
Year: 2018 PMID: 29852857 PMCID: PMC7040520 DOI: 10.2174/0929867325666180601101859
Source DB: PubMed Journal: Curr Med Chem ISSN: 0929-8673 Impact factor: 4.530
Nanoparticles in applications.
|
|
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Adagen® | Adenosine deaminase | PEG | n.a. | Severe combined immunodeficiency | 1990 | [ | ||||
| Neulasta®/Filgrastim | G-CSF | PEG | n.a. | Febrile neutropenia, cancer chemotherapy associated with neutropenia | 2002 | [ | ||||
| Oncaspar® | l-asparaginase | PEG | n.a. | Leukemia acute lymphoblastic leukemia | 1994 | [ | ||||
| Cimzia® | Certolizumab anti-TNFα Fab′ | PEG | n.a. | Crohn's disease rheumatoid arthritis | 2008 | [ | ||||
| Peg-intron® | Interferon alpha 2b | PEG | n.a. | Hepatitis C | 2001 | [ | ||||
| Pegasys® | Interferon alpha 2a | PEG | n.a. | Hepatitis C & B, HIV | 2002 | [ | ||||
| Mircera® | Epoetin® | PEG | n.a. | Anemia associated with chronic kidney disease | 2007 | [ | ||||
| Krystexxa® | Pegloticase | PEG | n.a. | Refractory chronic gout | 2010 | [ | ||||
| Omontys® | Peginesatide | PEG | n.a. | Anemia associated with chronic kidney disease | 2012 | [ | ||||
| Uricase-PEG 20 | Uricase | PEG | n.a. | Hyperuricemia associated with tumor lysis syndrome | 2009 | [ | ||||
| Macugen® | Anti-VEGF aptamer | PEG | n.a. | Age-related macular degeneration | 2004 | [ | ||||
| Somavert®/ Pegvisomant | Growth hormonereceptor antagonist | PEG | n.a. | Acromegaly | 2003 | [ | ||||
| BIND-014 | PLGA-Docetaxel | PEG+targeting ligand | 100 nm | Solid tumors | Phase II | [ | ||||
| CALAA-01 | Cyclodextrin containing polymer | PEG+targeting ligand | 50-70 nm | Solid tumors | Phase I | [ | ||||
| Erbitux®/EDVsPAC | Bacterially derived mini-cell + Paclitaxel bound to polyglutamate polymer | PEG+bispecific monoclonal antibody | 400 nm | Solid tumors | Phase II | [ | ||||
| Estrasorb® | Estradiol in soybean oil | PEG | 20-200 nm | Estrogen receptor | 2003 | [ | ||||
| CYT-6091: Cyt-immune | Gold | Human tumor necrosis factor alpha + PEG-SH | 75 nm | Advanced solid tumors | Phase I | [ | ||||
|
| ||||||||||
| Abraxane® | Paclitaxel | Albumin (immobilized) | 70-130 nm | Breast cancer, non-small cell lung cancer, pancreatic cancer | 2005 | [ | ||||
| SEL-068 | PLGA | Nicotine antigen T-helper cell peptide TLR agonist | 150–250 nm | Smoking cessation vaccine | Phase I | [ | ||||
|
| ||||||||||
| Resovist® | Iron oxide | Carboxydextrane | 60 nm | Imaging (MRI) | 2001 | [ | ||||
|
|
|
|
|
|
|
| ||||
| Venofer® | Iron oxide | Sucrose | 7 -23 nm | Anemia | 2000 | [ | ||||
| Cosmofer® | Iron oxide | Dextran | 10-15 nm | Anemia | 2008 | [ | ||||
| Ferrlecit® | Iron oxide | Sodium gluconate | 3-12 nm | Anemia | 1999 | [ | ||||
| Feridex® | Iron oxide | Dextran, mannitol, citrate | 120-180 nm | Imaging (MRI) | 1996 | [ | ||||
|
| ||||||||||
| Rexin-G® | Cytocidal dominant negative cyclin-G1 DNA construct | Pathotropic NP | 100 nm | Sarcoma, osteosarcoma pancreatic cancer | Phase IIa | [ | ||||
| Gastromark®/Lumirem® | Iron oxide | [N-(2-aminoethyl)-3-aminopropyl] siloxane | 300 nm | Imaging | 1996 | [ | ||||
Properties of several polysaccharides commonly used for coating or encapsulation of NPs. Reprinted with permission from Ref. [264].
|
|
|
|
|
|---|---|---|---|
| Alginate | Distributed widely in the cell walls of brown algae | Negative | OH,COOH |
| Chitosan | From the exoskeletons of shrimp and other crustaceans treated with sodium hydroxide | Positive | OH, NH2 |
| Dextran | First discovered by Louis Pasteur as a microbial product in wine | Neutral | OH |
| Hyaluronic acid | Distributed widely throughout connective, epithelial, and neural tissues | Negative | OH, COOH |
| Heparin | Extracted from animal tissues | Negative | OH, OSO3H |
| Mannan | Plant polysaccharide | Neutral | OH |
| Pullulan | Produced from starch by the fungus Aureobasidium pullulans | Neutral | OH |
| Starch | Produced by most green plants to store energy | Neutral | OH |